Unit
- Definition: Parkinson disease is a progressive neurodegenerative disorder characterized by motor symptoms such as tremor, rigidity, bradykinesia, and postural instability, along with a wide range of non-motor features. It results primarily from loss of dopamine-producing neurons in the substantia nigra pars compacta, leading to disrupted basal ganglia circuitry.
- Historical background: First described by James Parkinson in 1817 in his essay on shaking palsy, the condition was later named after him. Over two centuries of research have evolved understanding from a purely motor disorder to a complex multisystem condition involving genetic, environmental, and aging factors.
- Prevalence and impact: Parkinson disease is the second most common neurodegenerative disorder after Alzheimer disease, affecting approximately 1% of individuals over age 60. The global burden is increasing due to aging populations, with significant implications for healthcare systems, caregivers, and society.
- Clinical spectrum: The disease presents heterogeneously; some patients experience tremor-dominant forms with slower progression, while others have akinetic-rigid or postural instability gait difficulty subtypes that may progress more rapidly. Non-motor symptoms like anosmia, REM sleep behavior disorder, and constipation often precede motor signs by years.
- Pathological hallmark: Lewy bodies and Lewy neurites, composed of aggregated alpha-synuclein protein, are found in surviving neurons. The spread of alpha-synuclein pathology follows a predictable pattern through the brainstem, limbic system, and neocortex, correlating with clinical stage.
- Role of dopamine: Dopamine deficiency in the striatum leads to the classic motor triad. However, involvement of other neurotransmitters (serotonin, norepinephrine, acetylcholine) explains the broad non-motor symptom spectrum, including mood disturbances, autonomic dysfunction, and cognitive decline.
- Current treatment paradigm: Management is symptomatic and multidisciplinary, combining pharmacotherapy (levodopa, dopamine agonists, MAO-B inhibitors) with rehabilitation therapies, lifestyle modifications, and, in advanced cases, surgical interventions such as deep brain stimulation. No disease-modifying therapy exists yet.
- Importance of early diagnosis: Early detection allows timely initiation of symptomatic treatment, patient education, and planning for future care needs. Research into prodromal markers aims to identify individuals at risk before motor onset, opening a window for potential neuroprotective trials.
- Team-based care: Optimal Parkinson disease management requires a coordinated team including neurologists, movement disorder specialists, nurses, physical and occupational therapists, speech-language pathologists, social workers, and mental health professionals. Patient and caregiver involvement is central.
Terminology
- Bradykinesia
- Slowness of voluntary movement, often with reduced amplitude and speed, a cardinal motor feature of Parkinson disease.
- Lewy body
- Abnormal intracytoplasmic inclusion body composed of alpha-synuclein protein found in neurons, characteristic of Parkinson disease and related disorders.
- Prodromal period
- The phase before classical motor symptoms appear, during which non-motor features such as hyposmia, constipation, and REM sleep behavior disorder may emerge.
- Dopamine agonist
- A class of medications that mimic the action of dopamine by stimulating dopamine receptors, used to treat motor symptoms in Parkinson disease.
Quick Revision
- Parkinson disease is a progressive neurodegenerative disorder with motor and non-motor symptoms due to dopamine neuron loss.
- First described by James Parkinson in 1817; understanding has evolved to include multisystem involvement.
- Second most common neurodegenerative disease after Alzheimer, affecting 1% over 60.
- Pathological hallmark: Lewy bodies composed of alpha-synuclein; spread follows a predictable pattern.
- Current treatment is symptomatic and multidisciplinary; no disease-modifying therapy exists.